Myriad quizzed by Supreme Court justices

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Myriad quizzed by Supreme Court justices

In a landmark case with sweeping repercussions for medical research that's being closely watched around the globe, the US Supreme Court on Monday heard oral arguments on the patent eligibility of human genes

Association for Molecular Pathology v Myriad Genetics hinges on whether the building blocks of life that form the human genome are also intellectual property.

A coalition of plaintiffs that includes researchers, patients, and breast cancer and women's health groups argue that genetic material is a "product of nature" that is ineligible for patents.

Utah-based Myriad, whose supporters include the Biotechnology Industry Organization (BIO) and the Coalition for 21st Century Medicine, maintains that genetic material removed from the body through "invented" methods can be patented because it is no longer naturally occurring.

The lawsuit was brought by the ACLU and the Public Patent Foundation, a non-profit legal group affiliated with the Benjamin N Cardozo School of Law.

A District Court ruled in 2010 that Myriad’s patents related to the isolation of breast and ovarian cancer genes BRCA 1 and BRCA 2 were invalid. But the Federal Circuit reversed the decision in 2011 in a 2-1 decision.

During Monday's arguments, Gregory A Castanias, the attorney representing Myriad Genetics and head of Jones Day’s Federal Circuit practice, quickly found himself on the defensive. Justice Sonia Sotomayor immediately interrupted his opening remarks to express that it's "very, very difficult to see how you can patent a sequential numbering system (created) by nature."

Sotomayor has always been under the impression that to obtain a patent one must "add to what nature does”, she noted. "There was invention," Castanias responded, "in the decision of where to begin the gene and where to end the gene."

Justice Stephen Breyer lectured that if someone discovers a "satisfying new process to extract sap" from a tree or plant in the Amazon or discovers how to treat cancer with the sap, they can patent those things.

"What you can't patent is the sap itself," he said, underscoring the importance of keeping products of nature free from patents. "That's the framework that I'm bringing to the case," he added.

Drawing a comparison with a baseball bat that was "invented”, Chief Justice John Roberts suggested that Myriad didn't have to invent any DNA strands – it just snipped them. "You wouldn't even know where to snip without the Myriad invention," Castanias countered. Elena Kagan, the newest justice, asked whether another major scientific breakthrough, the first isolation of a chromosome, could have been patented. Castanias said “yes” with a caveat – if the chromosome “had a specific utility”.

Earlier in the proceedings, Justice Ruth Bader Ginsburg asked Christopher A Hansen, the attorney for the Association for Molecular Pathology, to explain the difference between a patent on aspirin or whooping cough medication and Myriad's patents.

"This court has used the example of gold," said Hansen, senior national staff counsel for the ACLU. "You can't patent gold because it's a product of nature." He later warned: "When you lock up a product of nature, it prevents industry from innovating and making new discoveries."

During an exchange with Hansen, Justice Antonin Scalia suggested that companies such as Myriad might lack the incentive to make significant financial investments in genetic research if they can't patent DNA. When Hansen surmised that companies would still invest to compete for Nobel prizes and recognition, Justice Kagan said she was hoping for a different answer: that companies would still conclude that such investments were worthwhile business decisions.

The Court is expected to issue its judgment in the case in the next few months. More information on the dispute is available on Managing IP's dedicated topic page.

more from across site and SHARED ros bottom lb

More from across our site

A flurry of hiring activity among UK firms suggests they are confident of mounting a serious challenge at the UPC
With the submission deadline approaching, we sat down with our research team to provide top tips on how to make your firm stand out
EA, owner of video games including Madden and The Sims, will be sold to a consortium including Saudi Arabia’s Public Investment Fund and a firm owned by Donald Trump’s son-in-law
New arrival marks Mewburn Ellis' second partner hire in ten days as firm looks to boost patent litigation and prosecution capabilities
In-house counsel and teams are invited to submit information for the 21st annual Managing IP Awards
The 2025 list of Rising Stars and Corporate Stars, produced by Managing IP’s accreditation title IP STARS, is now available
Eszter Szakács, partner at Danubia in Hungary, discusses women’s progression, workplace flexibility, and how to deal with imposter syndrome
Rob Fewery is a solicitor at Allwyn Entertainment in the UK
Piotr Rafalski is a patent attorney at Qemetica in Poland
Roshni Suchak is a legal counsel at SSP Group in the UK
Gift this article